PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
A copy of the Press Release titled "Panacea Biotec launches EasyFourPol in India and receives registration of Valganciclovir Powder for Oral Solution in Germany" being issued to the media etc. in this regard is enclosed for your kind reference and record please. PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialized During November, 2023 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Please find enclosed the data of shares dematerialised during November, 2023 along with the certificate obtained from Company''s RTA, Skyline Financial Services Pvt. Ltd. regarding shares dematerialised as on November 30, 2023. PANACEA BIOTEC LTD. - 531349 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith newspaper copies of the Extract of Statement of Unaudited Standalone & Consolidated Financial Results (Provisional) for quarter and half year ended September 30, 2023 published in the newspaper on November 11, 2023. PANACEA BIOTEC LTD. - 531349 - Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2023
Please find enclosed herewith the Unaudited Standalone and Consolidated Financial results (Provisional) of the Company for quarter and half year ended September 30, 2023, as approved by the Board of Directors in its meeting held today i.e. November 10, 2023 PANACEA BIOTEC LTD. - 531349 - Board Meeting Outcome for Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter And Half Year Ended September 30, 2023
We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. November 10, 2023, inter-alia, considered and approved the Unaudited Standalone and Consolidated Financial Results (Provisional) of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter and half year ended September 30, 2023. The same were also reviewed by the Audit Committee in its meeting held on November 09, 2023. A copy of the said statement of financial results along with the Limited Review Report is enclosed herewith. The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 01:25 P.M. PANACEA BIOTEC LTD. - 531349 - Details Of Shares Dematerialized During October, 2023 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018
Please find enclosed herewith the details of shares dematerialised during October, 2023 under Regulation 74(5) of the SEBI (Depositories and participants) Regulation, 2018
Panacea Biotec arm launches cancer drug in Canadian market; shares trade higher
Paclitaxel Protein-Bound Particles is indicated for the treatment of metastatic breast cancer, non-small cell lung cancer, and adenocarcinoma of the pancreas. PANACEA BIOTEC LTD. - 531349 - Launch Of Paclitaxel Protein-Bound Particles For Injectable Suspension (Albumin-Bound), A Generic Version Of Abraxane(r) By Its Material Wholly-Owned Subsidiary Company Viz. Panacea Biotec Pharma Ltd.
The Company is pleased to announce the launch of Paclitaxel Protein-Based Particles for Injectable Suspension (Albumin - Bound), a generic version of Abraxane in the Canadian market by its material wholly-owned subsidiary company viz. Panacea Biotec Pharma Ltd. through its strategic partner Apotex Inc., Canada. PANACEA BIOTEC LTD. - 531349 - Board Meeting Intimation for Approving The Standalone And Consolidated Unaudited Financial Results (Provisional) For The Quarter And Half Year Ended September 30, 2023
PANACEA BIOTEC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2023. The trading window of the Company shall remain closed for all Designated Persons of the Company till November 12, 2023
Panacea Biotech slumps 5% after US FDA issues 9 observations on Baddi facility
The USFDA inspected the unit from October 03-12.